Selecta Biosciences, Inc.
SELB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.02 | 0.21 |
| FCF Yield | -31.66% | -49.68% | -20.07% | -16.49% |
| EV / EBITDA | 0.00 | -0.43 | 5.88 | -64.15 |
| Quality | ||||
| ROIC | 0.00% | -39.03% | 9.80% | -12.83% |
| Gross Margin | 0.00% | 0.00% | 34.66% | 19.21% |
| Cash Conversion Ratio | 0.67 | 0.23 | -0.89 | 2.35 |
| Growth | ||||
| Revenue 3-Year CAGR | -29.44% | -100.00% | 88.28% | 133.57% |
| Free Cash Flow Growth | 36.21% | -56.45% | 46.59% | -280.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.76 | -4.24 | 17.19 |
| Interest Coverage | 0.00 | 30.50 | 4.80 | -1.62 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 8.18 | 0.00 | 30.56 | 41.34 |